Movement Alert｜Sanofi SA Intraday Rise 4.01% in Regular Trading, Q3 profit beat and strong Dupixent sales lifted shares

Market Focus10-30 22:17

On October 30, Sanofi SA rose 4.01% in Regular Trading, trading at $44.855/share, with turnover of $155.0 million.

The move followed third-quarter results that exceeded market expectations, alongside a second consecutive increase to full-year sales and profit guidance.

Key drivers cited in the company update included Dupixent sales of €5.7 billion in the quarter, up 34.8% year over year, which more than offset weakness in vaccines, where sales were €3.2 billion, down 6.6%. Lower-than-expected selling and promotion expenses also supported profit outperformance. Additional context showed Sanofi recently signed a letter of intent in Canada covering Dupixent in four additional indications, reinforcing expectations for further product expansion. The company also said it is seeking late-stage asset acquisitions to help address future patent-cliff pressure and plans to update strategic priorities before year-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment